Pooled analysis of NeoCARH and NeoCART trials: patient-reported outcomes in patients with early-stage breast cancer receiving platinum-based or anthracycline-based neoadjuvant chemotherapy

Pooled Analysis of NeoCARH and NeoCART Trials: Patient-Reported Outcomes in Early-Stage Breast Cancer

Background

Neoadjuvant chemotherapy is a standard treatment for early-stage breast cancer (EBC) that is triple-negative or human epidermal growth factor receptor 2 positive (HER2 +). However, there is limited data comparing the impact of anthracycline-based and platinum-based regimens on patients’ health-related quality of life (HRQoL).

Study Methods

This analysis included patients from two prospective randomized controlled trials, neoCARH and neoCART, who received either anthracycline-based or platinum-based neoadjuvant chemotherapy. HRQoL was assessed using validated questionnaires at baseline, after chemotherapy, and at 1 and 2 years after diagnosis.

Key Findings

After neoadjuvant chemotherapy, patients in the platinum-based group showed a smaller decrease in HRQoL compared to those in the anthracycline-based group. The platinum-based group demonstrated superior outcomes in most assessed domains of interest.

Conclusion

Both platinum-based and anthracycline-based regimens led to worsened HRQoL after neoadjuvant chemotherapy, but the platinum-based group had relatively better HRQoL compared to the anthracycline-based group.

Clinical Trial Registration

ClinicalTrials.gov: NCT03140553 (neoCARH) and NCT03154749 (neoCART)

Practical Solutions and Value

Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical protocols and research into an easily accessible knowledge base for clinicians. Additionally, our mobile apps support scheduling, treatment monitoring, and telemedicine, streamlining operations and improving patient care.